---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-059668"
form_type: "8-K"
ticker: null
cik: "0001061027"
company_name: "Viracta Therapeutics, Inc."
filed_at: "2024-05-14T23:59:59+00:00"
generated_at: "2026-06-02T00:12:33.345404+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Viracta Therapeutics appoints Michael Faerm as CFO, base salary $480K with stock options

## Summary
- Michael Faerm appointed CFO effective May 13, 2024; previously interim CFO at Harpoon Therapeutics.
- Annual base salary $480,000, target bonus up to 40% of base salary.
- Initial option to purchase 500,000 shares of common stock, vesting over 4 years.
- Additional option for 340,000 shares if financing extends runway through FY2025 by Dec 31, 2024.
- Board increased shares reserved under Inducement Plan by 1,200,000, total 3,575,000 shares.

## SEC filing metadata
- accession: 0000950170-24-059668
- form_type: 8-K
- cik: 0001061027
- company_name: Viracta Therapeutics, Inc.
- filed_at: 2024-05-14T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1061027/000095017024059668/0000950170-24-059668-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1061027/000095017024059668/virx-20240511.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-059668
- JSON: https://secwatch.observer/filing/0000950170-24-059668.json
- Plain text: https://secwatch.observer/filing/0000950170-24-059668.txt

## Key facts
- Executive change
  Melody Burcar changed role as Senior Vice President of Finance at Viracta Therapeutics, Inc..
  - Action: no longer serve
  - Role: Senior Vice President of Finance
  source text: Melody Burcar, the Company’s Senior Vice President of Finance, will no longer serve as the Company’s interim principal financial officer and interim principal accounting officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1061027/000095017024059668/0000950170-24-059668-index.htm
- Executive change
  Michael Faerm was appointed as Chief Financial Officer at Viracta Therapeutics, Inc..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: On May 11, 2024, the Board of Directors ("Board") of Viracta Therapeutics, Inc. (the "Company") appointed Michael Faerm to serve as the Company’s Chief Financial Officer, effective May 13, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1061027/000095017024059668/0000950170-24-059668-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.